JSF 4439
Alternative Names: JSF-4439Latest Information Update: 13 Sep 2023
Price :
$50 *
At a glance
- Originator Collaborations Pharmaceuticals; Rutgers
- Developer Collaborations Pharmaceuticals
- Class Antibacterials; Chlorobenzenes; Heterocyclic acids; Heterocyclic compounds; Isoindoles; Small molecules
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Gonorrhoea
Most Recent Events
- 18 Aug 2023 JSF 4439 is available for licensing as of 18 Aug 2023. https://www.collaborationspharma.com/partnerships
- 13 Jul 2020 Early research in Gonorrhoea in USA (unspecified route)
- 13 Jul 2020 Pharmacokinetics and antimicrobial data from early research in Gonorrhoeae released by Collaborations Pharmaceuticals